We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Catalyst Pharmaceuticals, Inc today announced that the first patient has been enrolled into its Phase 3 clinical trial to evaluate the efficacy and safety of Firdapse® in patients with MuSK antibody positive Myasthenia Gravis